Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 7/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | ULK1 | O75385 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 9/20 | 0.37 |
| ▸ | FEN1 | P39748 | 8/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17310146 | 0.78 | KDM4E (0.38) | ZAP70BRD4CDK7CDK9ALOX5AP | |
| SCHEMBL4094489 | 0.75 | ZAP70 (0.48) | ZAP70BRD4ULK1CDK7CDK9 | |
| SCHEMBL13849392 | 0.74 | ZAP70 (0.57) | ZAP70BRD4ULK1CDK7CDK9 | |
| SCHEMBL29777617 | 0.73 | ZAP70 (0.44) | ZAP70CDK7CDK9EGFR | |
| SCHEMBL4107109 | 0.71 | ZAP70 (0.50) | ZAP70CDK7CDK9EGFR | |
| SCHEMBL17404669 | 0.70 | ALK (0.52) | ZAP70ULK1EGFR | |
| SCHEMBL12901102 | 0.70 | SLC22A12 (0.45) | ZAP70ALOX5APFEN1 | |
| SCHEMBL17310031 | 0.70 | MAPT (0.53) | — | |
| SCHEMBL1232414 | 0.69 | ZAP70 (0.40) | ZAP70ALOX5APFEN1 | |
| SCHEMBL17310219 | 0.68 | MEN1 (0.44) | ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2952510-B1 | SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2018-12-26 | — | — | EP | disclosed |
| US-9708295-B2 | Substituted 2-aminopyridine protein kinase inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-07-18 | — | — | US | disclosed |
| US-9708295-B2 | Substituted 2-aminopyridine protein kinase inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-07-18 | — | — | US | disclosed |
| US-9708295-B2 | Substituted 2-aminopyridine protein kinase inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-07-18 | — | — | US | disclosed |
| US-20160002205-A1 | SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD (CN) | 2016-01-07 | — | — | US | disclosed |
| US-20160002205-A1 | SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD (CN) | 2016-01-07 | — | — | US | disclosed |
| US-20160002205-A1 | SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD (CN) | 2016-01-07 | — | — | US | disclosed |
| EP-2952510-A1 | SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd (CN) | 2015-12-09 | — | — | EP | disclosed |
| CN-104968654-A | Substituted 2-aminopyridine protein kinase inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD | 2015-10-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002205-A1 | SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | PACSIN2, MAPKAPK2, PRKCA | ZAP70 460/4885BRD4 1289/4885ULK1 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.